Article info
Commentary
Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency
- Correspondence to Dr Bradley J Monk, Virginia G Piper Cancer Center – Biltmore Cancer Center, Phoenix, AZ 85016, USA; bmonk{at}gog.org
Citation
Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency
Publication history
- Received March 20, 2023
- Accepted March 23, 2023
- First published April 6, 2023.
Article Versions
- You are currently viewing a Previous version of this article (6 April 2023).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.